Switch to:
Also traded in: Austria, Brazil, Germany, Mexico, Switzerland, UK

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash-to-Debt 0.62
BIIB's Cash-to-Debt is ranked lower than
86% of the 1056 Companies
in the Global Biotechnology industry.

( Industry Median: 73.06 vs. BIIB: 0.62 )
Ranked among companies with meaningful Cash-to-Debt only.
BIIB' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.25  Med: 4.83 Max: No Debt
Current: 0.62
0.25
No Debt
Equity-to-Asset 0.53
BIIB's Equity-to-Asset is ranked lower than
68% of the 770 Companies
in the Global Biotechnology industry.

( Industry Median: 0.68 vs. BIIB: 0.53 )
Ranked among companies with meaningful Equity-to-Asset only.
BIIB' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.48  Med: 0.76 Max: 0.96
Current: 0.53
0.48
0.96
Debt-to-Equity 0.47
BIIB's Debt-to-Equity is ranked lower than
65% of the 488 Companies
in the Global Biotechnology industry.

( Industry Median: 0.27 vs. BIIB: 0.47 )
Ranked among companies with meaningful Debt-to-Equity only.
BIIB' s Debt-to-Equity Range Over the Past 10 Years
Min: 0.01  Med: 0.13 Max: 0.79
Current: 0.47
0.01
0.79
Debt-to-EBITDA 0.91
BIIB's Debt-to-EBITDA is ranked higher than
68% of the 213 Companies
in the Global Biotechnology industry.

( Industry Median: 1.97 vs. BIIB: 0.91 )
Ranked among companies with meaningful Debt-to-EBITDA only.
BIIB' s Debt-to-EBITDA Range Over the Past 10 Years
Min: 0.13  Med: 0.64 Max: 1.2
Current: 0.91
0.13
1.2
Interest Coverage 20.83
BIIB's Interest Coverage is ranked lower than
80% of the 521 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. BIIB: 20.83 )
Ranked among companies with meaningful Interest Coverage only.
BIIB' s Interest Coverage Range Over the Past 10 Years
Min: 19.19  Med: 29.96 Max: 92.25
Current: 20.83
19.19
92.25
Piotroski F-Score: 5
Altman Z-Score: 5.49
Beneish M-Score: -2.55
WACC vs ROIC
8.57%
19.51%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 9/10

vs
industry
vs
history
Operating Margin % 42.57
BIIB's Operating Margin % is ranked higher than
95% of the 800 Companies
in the Global Biotechnology industry.

( Industry Median: -98.02 vs. BIIB: 42.57 )
Ranked among companies with meaningful Operating Margin % only.
BIIB' s Operating Margin % Range Over the Past 10 Years
Min: 16  Med: 29.8 Max: 49.25
Current: 42.57
16
49.25
Net Margin % 20.69
BIIB's Net Margin % is ranked higher than
88% of the 800 Companies
in the Global Biotechnology industry.

( Industry Median: -88.19 vs. BIIB: 20.69 )
Ranked among companies with meaningful Net Margin % only.
BIIB' s Net Margin % Range Over the Past 10 Years
Min: 19.11  Med: 30.99 Max: 34.49
Current: 20.69
19.11
34.49
ROE % 20.92
BIIB's ROE % is ranked higher than
93% of the 969 Companies
in the Global Biotechnology industry.

( Industry Median: -40.23 vs. BIIB: 20.92 )
Ranked among companies with meaningful ROE % only.
BIIB' s ROE % Range Over the Past 10 Years
Min: 13.81  Med: 20.75 Max: 35.15
Current: 20.92
13.81
35.15
ROA % 11.28
BIIB's ROA % is ranked higher than
92% of the 1062 Companies
in the Global Biotechnology industry.

( Industry Median: -32.55 vs. BIIB: 11.28 )
Ranked among companies with meaningful ROA % only.
BIIB' s ROA % Range Over the Past 10 Years
Min: 9.16  Med: 14.4 Max: 22.42
Current: 11.28
9.16
22.42
ROC (Joel Greenblatt) % 148.25
BIIB's ROC (Joel Greenblatt) % is ranked higher than
95% of the 1021 Companies
in the Global Biotechnology industry.

( Industry Median: -430.94 vs. BIIB: 148.25 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
BIIB' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: 67.06  Med: 124.24 Max: 214.75
Current: 148.25
67.06
214.75
3-Year Revenue Growth Rate 17.10
BIIB's 3-Year Revenue Growth Rate is ranked higher than
64% of the 604 Companies
in the Global Biotechnology industry.

( Industry Median: 4.00 vs. BIIB: 17.10 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
BIIB' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -19.4  Med: 20.2 Max: 95.1
Current: 17.1
-19.4
95.1
3-Year EBITDA Growth Rate 15.50
BIIB's 3-Year EBITDA Growth Rate is ranked higher than
67% of the 722 Companies
in the Global Biotechnology industry.

( Industry Median: 3.10 vs. BIIB: 15.50 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
BIIB' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: 0  Med: 25 Max: 127.9
Current: 15.5
0
127.9
3-Year EPS without NRI Growth Rate -1.20
BIIB's 3-Year EPS without NRI Growth Rate is ranked lower than
57% of the 704 Companies
in the Global Biotechnology industry.

( Industry Median: 4.20 vs. BIIB: -1.20 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
BIIB' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: 0  Med: 25.6 Max: 205.2
Current: -1.2
0
205.2
GuruFocus has detected 1 Warning Sign with Biogen Inc BIIB.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» BIIB's 30-Y Financials

Financials (Next Earnings Date: 2018-04-25)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q1 2017

BIIB Guru Trades in Q1 2017

Leucadia National 1,716 sh (New)
Richard Pzena 759 sh (New)
Jeremy Grantham 1,480 sh (New)
Manning & Napier Advisors, Inc 122,675 sh (New)
Caxton Associates 1,200 sh (New)
Pioneer Investments 54,344 sh (New)
Ray Dalio 45,447 sh (New)
Steven Cohen 216,470 sh (+304.30%)
Jim Simons 848,961 sh (+20.00%)
Joel Greenblatt 275,460 sh (+14.63%)
Ronald Muhlenkamp 25,557 sh (+9.79%)
Ken Fisher 109,414 sh (+7.39%)
Jeff Auxier 25,875 sh (+2.25%)
John Buckingham 17,061 sh (+0.75%)
Vanguard Health Care Fund 3,841,803 sh (unchged)
Ronald Muhlenkamp 3,000 sh (unchged)
Ron Baron 6,625 sh (unchged)
First Eagle Investment 1,000 sh (unchged)
Mairs and Power 1,025 sh (unchged)
David Dreman Sold Out
First Eagle Investment Sold Out
HOTCHKIS & WILEY 286,572 sh (-0.08%)
PRIMECAP Management 15,477,424 sh (-0.69%)
Richard Snow 186,104 sh (-3.25%)
John Burbank 5,671 sh (-3.95%)
Frank Sands 2,475,937 sh (-3.99%)
Mario Gabelli 1,772 sh (-5.34%)
Lee Ainslie 9,610 sh (-11.67%)
John Hussman 250 sh (-28.57%)
Murray Stahl 4,645 sh (-30.20%)
Andreas Halvorsen 688,765 sh (-64.10%)
Eric Mindich 111,191 sh (-66.09%)
John Paulson 17,300 sh (-66.86%)
Paul Tudor Jones 1,752 sh (-77.58%)
Eaton Vance Worldwide Health Sciences Fund 154,569 sh (-7.17%)
» More
Q2 2017

BIIB Guru Trades in Q2 2017

David Dreman 3,705 sh (New)
John Hussman 10,000 sh (+3900.00%)
Jeremy Grantham 24,484 sh (+1554.32%)
Manning & Napier Advisors, Inc 814,369 sh (+563.84%)
Steven Cohen 892,101 sh (+312.11%)
Ron Baron 12,935 sh (+95.25%)
Lee Ainslie 15,230 sh (+58.48%)
Caxton Associates 1,500 sh (+25.00%)
Richard Snow 215,182 sh (+15.62%)
Jeff Auxier 28,170 sh (+8.87%)
Mairs and Power 1,053 sh (+2.73%)
HOTCHKIS & WILEY 286,572 sh (unchged)
Ronald Muhlenkamp 3,000 sh (unchged)
Jeremy Grantham 80,000 sh (unchged)
Murray Stahl 4,645 sh (unchged)
Richard Pzena Sold Out
Leucadia National Sold Out
John Burbank Sold Out
Andreas Halvorsen Sold Out
Paul Tudor Jones Sold Out
John Paulson Sold Out
John Buckingham 17,055 sh (-0.04%)
Ronald Muhlenkamp 25,545 sh (-0.05%)
Ken Fisher 109,129 sh (-0.26%)
PRIMECAP Management 15,391,401 sh (-0.56%)
Ray Dalio 44,981 sh (-1.03%)
Mario Gabelli 1,750 sh (-1.24%)
Vanguard Health Care Fund 3,784,603 sh (-1.49%)
Jim Simons 762,861 sh (-10.14%)
Joel Greenblatt 162,464 sh (-41.02%)
Frank Sands 1,278,163 sh (-48.38%)
Pioneer Investments 26,290 sh (-51.62%)
Eaton Vance Worldwide Health Sciences Fund 132,800 sh (-14.08%)
» More
Q3 2017

BIIB Guru Trades in Q3 2017

David Carlson 95,000 sh (New)
Stanley Druckenmiller 48,000 sh (New)
Pioneer Investments 46,690 sh (+77.60%)
Ron Baron 12,951 sh (+0.12%)
John Buckingham 17,073 sh (+0.11%)
Ronald Muhlenkamp 3,000 sh (unchged)
Mairs and Power 1,053 sh (unchged)
Jeremy Grantham 80,000 sh (unchged)
David Dreman 3,705 sh (unchged)
Murray Stahl 4,645 sh (unchged)
John Hussman Sold Out
Lee Ainslie Sold Out
Caxton Associates Sold Out
Jeff Auxier 28,145 sh (-0.09%)
Ken Fisher 107,864 sh (-1.16%)
PRIMECAP Management 15,212,914 sh (-1.16%)
Ray Dalio 44,198 sh (-1.74%)
Vanguard Health Care Fund 3,712,503 sh (-1.91%)
Richard Snow 210,459 sh (-2.19%)
Ronald Muhlenkamp 24,547 sh (-3.91%)
HOTCHKIS & WILEY 274,772 sh (-4.12%)
Mario Gabelli 1,675 sh (-4.29%)
Frank Sands 1,207,172 sh (-5.55%)
Manning & Napier Advisors, Inc 737,735 sh (-9.41%)
Steven Cohen 507,922 sh (-43.06%)
Joel Greenblatt 63,039 sh (-61.20%)
Jim Simons 120,161 sh (-84.25%)
Jeremy Grantham 1,480 sh (-93.96%)
Eaton Vance Worldwide Health Sciences Fund 117,233 sh (-11.72%)
» More
Q4 2017

BIIB Guru Trades in Q4 2017

Richard Pzena 931 sh (New)
Leucadia National 1,537 sh (New)
Caxton Associates 2,866 sh (New)
Paul Tudor Jones 3,354 sh (New)
Pioneer Investments 245,830 sh (+426.52%)
Stanley Druckenmiller 109,400 sh (+127.92%)
Joel Greenblatt 87,874 sh (+39.40%)
Ron Baron 14,868 sh (+14.80%)
John Buckingham 17,300 sh (+1.33%)
Ronald Muhlenkamp 24,682 sh (+0.55%)
Richard Snow 211,462 sh (+0.48%)
Jeff Auxier 28,155 sh (+0.04%)
David Carlson 95,000 sh (unchged)
David Dreman 3,705 sh (unchged)
Murray Stahl 4,645 sh (unchged)
Eaton Vance Worldwide Health Sciences Fund 117,233 sh (unchged)
Ray Dalio Sold Out
Jim Simons Sold Out
PRIMECAP Management 15,109,231 sh (-0.68%)
HOTCHKIS & WILEY 271,672 sh (-1.13%)
Mario Gabelli 1,650 sh (-1.49%)
Vanguard Health Care Fund 3,636,003 sh (-2.06%)
Mairs and Power 1,025 sh (-2.66%)
Frank Sands 1,138,777 sh (-5.67%)
Ken Fisher 99,280 sh (-7.96%)
Jeremy Grantham 1,300 sh (-12.16%)
Steven Cohen 252,319 sh (-50.32%)
» More
» Details

Insider Trades

Latest Guru Trades with BIIB

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Vanguard Health Care Fund 2017-12-31 Reduce -2.06%0.05%$307.64 - $344.58 $ 263.02-18%3,636,003
HOTCHKIS & WILEY 2017-12-31 Reduce -1.13%$307.64 - $344.58 $ 263.02-18%271,672
Ken Fisher 2017-12-31 Reduce -7.96%$307.64 - $344.58 $ 263.02-18%99,280
Joel Greenblatt 2017-12-31 Add 39.40%0.12%$307.64 - $344.58 $ 263.02-18%87,874
Ronald Muhlenkamp 2017-12-31 Add 0.55%0.01%$307.64 - $344.58 $ 263.02-18%24,682
Ron Baron 2017-12-31 Add 14.80%$307.64 - $344.58 $ 263.02-18%14,868
Mario Gabelli 2017-12-31 Reduce -1.49%$307.64 - $344.58 $ 263.02-18%1,650
Leucadia National 2017-12-31 New Buy0.04%$307.64 - $344.58 $ 263.02-18%1,537
Richard Pzena 2017-12-31 New Buy$307.64 - $344.58 $ 263.02-18%931
Vanguard Health Care Fund 2017-09-30 Reduce -1.91%0.04%$271.76 - $329.69 $ 263.02-11%3,712,503
HOTCHKIS & WILEY 2017-09-30 Reduce -4.12%0.01%$271.76 - $329.69 $ 263.02-11%274,772
Ken Fisher 2017-09-30 Reduce -1.16%$271.76 - $329.69 $ 263.02-11%107,864
Joel Greenblatt 2017-09-30 Reduce -61.20%0.38%$271.76 - $329.69 $ 263.02-11%63,039
Ronald Muhlenkamp 2017-09-30 Reduce -3.91%0.08%$271.76 - $329.69 $ 263.02-11%24,547
Ron Baron 2017-09-30 Add 0.12%$271.76 - $329.69 $ 263.02-11%12,951
Mario Gabelli 2017-09-30 Reduce -4.29%$271.76 - $329.69 $ 263.02-11%1,675
Vanguard Health Care Fund 2017-06-30 Reduce -1.49%0.03%$246.54 - $286.89 $ 263.02-1%3,784,603
Joel Greenblatt 2017-06-30 Reduce -41.02%0.39%$246.54 - $286.89 $ 263.02-1%162,464
Ken Fisher 2017-06-30 Reduce -0.26%$246.54 - $286.89 $ 263.02-1%109,129
Ronald Muhlenkamp 2017-06-30 Reduce -0.05%$246.54 - $286.89 $ 263.02-1%25,545
Ron Baron 2017-06-30 Add 95.25%0.01%$246.54 - $286.89 $ 263.02-1%12,935
David Dreman 2017-06-30 New Buy0.55%$246.54 - $286.89 $ 263.02-1%3,705
Mario Gabelli 2017-06-30 Reduce -1.24%$246.54 - $286.89 $ 263.02-1%1,750
John Paulson 2017-06-30 Sold Out 0.06%$246.54 - $286.89 $ 263.02-1%0
Leucadia National 2017-06-30 Sold Out 0.04%$246.54 - $286.89 $ 263.02-1%0
Richard Pzena 2017-06-30 Sold Out $246.54 - $286.89 $ 263.02-1%0
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 325414    SIC: 2836
Compare:ASX:CSL, NAS:CELG, NAS:VRTX, LSE:SHP, XKRX:068270, NAS:REGN, XKRX:207940, NAS:ALXN, NAS:INCY, XMCE:GRF.P, NAS:NKTR, HKSE:01177, SZSE:002252, XBRU:UCB, OCSE:NZYM B, NAS:GILD, NAS:BMRN, NAS:ALNY, OCSE:GEN, NAS:BIVV » details
Traded in other countries:BIIB.Austria, BIIB34.Brazil, IDP.Germany, BIIB.Mexico, BIIB.Switzerland, 0R1B.UK,
Headquarter Location:USA
Biogen Inc is a biopharmaceutical company. It is engaged in discovering, developing, manufacturing and delivering therapies to patients for the treatment of neurological, rare and autoimmune diseases.

Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen markets novel MS drugs Tysabri and Tecfidera independently. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis.

Top Ranked Articles about Biogen Inc

Factors of Influence in 2018, Key Indicators and Opportunity within McDonald's, Biogen, Freeport-McMoRan, Community Health, Enphase Energy, and Exxon Mobil — New Research Emphasizes Economic Growth
AbbVie Settles Patent Dispute with Biogen Biogen's Imraldi is expected to be launched in Europe in October
AbbVie Inc. (NYSE:ABBV) has inked an agreement with Biogen Inc. (NASDAQ:BIIB) and its collaborator Samsung Bioepis, as part of a settlement of a patent conflict over its biosimilar Humira. Read more...
Multiple Sclerosis Relapse Drug Is Pulled After Patient Safety Concerns Biogen and AbbVie collaborate to produce Zinbryta, a medication that treats a relapse in multiple sclerosis
Biogen (NASDAQ:BIIB) together with collaborator AbbVie (NYSE:ABBV) are yanking the multiple sclerosis drug Zinbryta (daclizumab) from worldwide markets after alarming reports of meningoencephalitis and inflammatory encephalitis among patients. Biogen reported the action on its website. Read more...
Richard Pzena’s Top 5 New Buys of the 4th Quarter Guru reports quarterly portfolio
Pzena Investment Management leader Richard Pzena (Trades, Portfolio) released his fourth-quarter portfolio last week, disclosing he opened nine new positions. Read more...
Consolidated Research: 2018 Summary Expectations for Kimball Electronics, Madrigal Pharmaceuticals, American Railcar Industries, H&R Block, Biogen, and Equinix — Fundamental Analysis, Key Performance Indications
Wall Street Bull After GDP Numbers Colgate-Palmolive meets profits but misses sales
U.S. stock markets are set to open higher on Friday, amid the U.S. economy expanded at a 2.6% annual pace in the fourth quarter. GDP fell short of estimates explained by a lower inventory production and a bigger trade deficit, with imports doubling exports, 13.9% and 6.9%, respectively. Further, consumer spending increased by 3.8% and investment in new housing rose11.6%. Read more...
Five Cheap Stocks With Growing Book Value Undervalued Stocks boosting their BV/S
According to the GuruFocus All-In-One Screener, the following companies have grown their book value per share (BV/S) over the past decade. Read more...
Janssen, AbbVie's Imbruvica Achieves PFS in Innovate Study The primary endpoints was achieved on patients affected with Waldenström's macroglobulinemia at the end of the Phase 3 of the clinical trial
The progression-free survival (or PFS) primary endpoint was successfully met by researchers of Janssen – a unit of Johnson & Johnson's (NYSE:JNJ) Pharmaceutical Research and Development – at the end of Phase 3 of a clinical trial, called Innovate, Janssen reported yesterday Dec. 5. Read more...
Primecap Management Buys Alkermes Biopharma Market-beating, media-shy firm picks biopharma with several drugs in final stages of approval
Index-beating firm Primecap Management disclosed today that it boosted its position in Alkermes Plc (NASDAQ:ALKS), a biopharmaceutical company, by 33.11% on Nov. 20. Read more...
Recent Analysis Shows Aflac, Biogen, Oasis Petroleum, Twilio, Neothetics, and McDonald's Market Influences — Renewed Outlook, Key Drivers of Growth

Ratios

vs
industry
vs
history
PE Ratio 22.01
BIIB's PE Ratio is ranked higher than
60% of the 260 Companies
in the Global Biotechnology industry.

( Industry Median: 29.83 vs. BIIB: 22.01 )
Ranked among companies with meaningful PE Ratio only.
BIIB' s PE Ratio Range Over the Past 10 Years
Min: 10.8  Med: 20.66 Max: 44.78
Current: 22.01
10.8
44.78
Forward PE Ratio 10.66
BIIB's Forward PE Ratio is ranked higher than
87% of the 71 Companies
in the Global Biotechnology industry.

( Industry Median: 24.45 vs. BIIB: 10.66 )
Ranked among companies with meaningful Forward PE Ratio only.
N/A
PE Ratio without NRI 22.01
BIIB's PE Ratio without NRI is ranked higher than
61% of the 255 Companies
in the Global Biotechnology industry.

( Industry Median: 30.45 vs. BIIB: 22.01 )
Ranked among companies with meaningful PE Ratio without NRI only.
BIIB' s PE Ratio without NRI Range Over the Past 10 Years
Min: 10.8  Med: 20.66 Max: 44.51
Current: 22.01
10.8
44.51
PB Ratio 4.40
BIIB's PB Ratio is ranked lower than
52% of the 954 Companies
in the Global Biotechnology industry.

( Industry Median: 4.51 vs. BIIB: 4.40 )
Ranked among companies with meaningful PB Ratio only.
BIIB' s PB Ratio Range Over the Past 10 Years
Min: 1.71  Med: 4.65 Max: 8.84
Current: 4.4
1.71
8.84
PS Ratio 4.55
BIIB's PS Ratio is ranked higher than
71% of the 733 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. BIIB: 4.55 )
Ranked among companies with meaningful PS Ratio only.
BIIB' s PS Ratio Range Over the Past 10 Years
Min: 2.58  Med: 5.49 Max: 14.56
Current: 4.55
2.58
14.56
Price-to-Free-Cash-Flow 21.42
BIIB's Price-to-Free-Cash-Flow is ranked higher than
60% of the 128 Companies
in the Global Biotechnology industry.

( Industry Median: 33.20 vs. BIIB: 21.42 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
BIIB' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 9.25  Med: 18.96 Max: 36.13
Current: 21.42
9.25
36.13
Price-to-Operating-Cash-Flow 12.26
BIIB's Price-to-Operating-Cash-Flow is ranked higher than
77% of the 196 Companies
in the Global Biotechnology industry.

( Industry Median: 30.32 vs. BIIB: 12.26 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
BIIB' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 7.22  Med: 15.26 Max: 32.48
Current: 12.26
7.22
32.48
EV-to-EBIT 10.76
BIIB's EV-to-EBIT is ranked higher than
74% of the 262 Companies
in the Global Biotechnology industry.

( Industry Median: 24.43 vs. BIIB: 10.76 )
Ranked among companies with meaningful EV-to-EBIT only.
BIIB' s EV-to-EBIT Range Over the Past 10 Years
Min: 7.5  Med: 14 Max: 32.2
Current: 10.76
7.5
32.2
EV-to-EBITDA 8.90
BIIB's EV-to-EBITDA is ranked higher than
77% of the 287 Companies
in the Global Biotechnology industry.

( Industry Median: 21.70 vs. BIIB: 8.90 )
Ranked among companies with meaningful EV-to-EBITDA only.
BIIB' s EV-to-EBITDA Range Over the Past 10 Years
Min: 6.1  Med: 11.5 Max: 26
Current: 8.9
6.1
26
EV-to-Revenue 4.71
BIIB's EV-to-Revenue is ranked higher than
72% of the 777 Companies
in the Global Biotechnology industry.

( Industry Median: 13.46 vs. BIIB: 4.71 )
Ranked among companies with meaningful EV-to-Revenue only.
BIIB' s EV-to-Revenue Range Over the Past 10 Years
Min: 2.5  Med: 5.5 Max: 14.6
Current: 4.71
2.5
14.6
PEG Ratio 0.84
BIIB's PEG Ratio is ranked higher than
77% of the 105 Companies
in the Global Biotechnology industry.

( Industry Median: 2.48 vs. BIIB: 0.84 )
Ranked among companies with meaningful PEG Ratio only.
BIIB' s PEG Ratio Range Over the Past 10 Years
Min: 0.31  Med: 0.76 Max: 4.31
Current: 0.84
0.31
4.31
Shiller PE Ratio 29.30
BIIB's Shiller PE Ratio is ranked higher than
70% of the 79 Companies
in the Global Biotechnology industry.

( Industry Median: 44.16 vs. BIIB: 29.30 )
Ranked among companies with meaningful Shiller PE Ratio only.
BIIB' s Shiller PE Ratio Range Over the Past 10 Years
Min: 28.69  Med: 74.47 Max: 492.6
Current: 29.3
28.69
492.6
Current Ratio 2.34
BIIB's Current Ratio is ranked lower than
70% of the 1035 Companies
in the Global Biotechnology industry.

( Industry Median: 4.21 vs. BIIB: 2.34 )
Ranked among companies with meaningful Current Ratio only.
BIIB' s Current Ratio Range Over the Past 10 Years
Min: 1.08  Med: 3.96 Max: 19.93
Current: 2.34
1.08
19.93
Quick Ratio 2.07
BIIB's Quick Ratio is ranked lower than
69% of the 1035 Companies
in the Global Biotechnology industry.

( Industry Median: 3.92 vs. BIIB: 2.07 )
Ranked among companies with meaningful Quick Ratio only.
BIIB' s Quick Ratio Range Over the Past 10 Years
Min: 0.97  Med: 3.44 Max: 19.93
Current: 2.07
0.97
19.93
Days Inventory 199.84
BIIB's Days Inventory is ranked lower than
75% of the 498 Companies
in the Global Biotechnology industry.

( Industry Median: 126.17 vs. BIIB: 199.84 )
Ranked among companies with meaningful Days Inventory only.
BIIB' s Days Inventory Range Over the Past 10 Years
Min: 199.47  Med: 238.11 Max: 266.3
Current: 199.84
199.47
266.3
Days Sales Outstanding 68.98
BIIB's Days Sales Outstanding is ranked higher than
59% of the 656 Companies
in the Global Biotechnology industry.

( Industry Median: 64.11 vs. BIIB: 68.98 )
Ranked among companies with meaningful Days Sales Outstanding only.
BIIB' s Days Sales Outstanding Range Over the Past 10 Years
Min: 39.79  Med: 52.25 Max: 68.98
Current: 68.98
39.79
68.98
Days Payable 82.85
BIIB's Days Payable is ranked higher than
61% of the 456 Companies
in the Global Biotechnology industry.

( Industry Median: 62.86 vs. BIIB: 82.85 )
Ranked among companies with meaningful Days Payable only.
BIIB' s Days Payable Range Over the Past 10 Years
Min: 68.59  Med: 95.56 Max: 148.21
Current: 82.85
68.59
148.21

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio 3.40
BIIB's 3-Year Average Share Buyback Ratio is ranked higher than
99% of the 768 Companies
in the Global Biotechnology industry.

( Industry Median: -13.20 vs. BIIB: 3.40 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
BIIB' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -92.1  Med: 0.6 Max: 30.9
Current: 3.4
-92.1
30.9

Valuation & Return

vs
industry
vs
history
Price-to-Tangible-Book 13.56
BIIB's Price-to-Tangible-Book is ranked lower than
80% of the 874 Companies
in the Global Biotechnology industry.

( Industry Median: 5.88 vs. BIIB: 13.56 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
BIIB' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 0.2  Med: 5.06 Max: 24.7
Current: 13.56
0.2
24.7
Price-to-Intrinsic-Value-Projected-FCF 1.33
BIIB's Price-to-Intrinsic-Value-Projected-FCF is ranked higher than
80% of the 179 Companies
in the Global Biotechnology industry.

( Industry Median: 3.54 vs. BIIB: 1.33 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
BIIB' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 0.18  Med: 1.76 Max: 12.82
Current: 1.33
0.18
12.82
Price-to-Intrinsic-Value-DCF (Earnings Based) 0.77
BIIB's Price-to-Intrinsic-Value-DCF (Earnings Based) is ranked higher than
87% of the 30 Companies
in the Global Biotechnology industry.

( Industry Median: 1.64 vs. BIIB: 0.77 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-DCF (Earnings Based) only.
BIIB' s Price-to-Intrinsic-Value-DCF (Earnings Based) Range Over the Past 10 Years
Min: 0.54  Med: 0.77 Max: 0.94
Current: 0.77
0.54
0.94
Price-to-Median-PS-Value 0.83
BIIB's Price-to-Median-PS-Value is ranked higher than
57% of the 614 Companies
in the Global Biotechnology industry.

( Industry Median: 1.00 vs. BIIB: 0.83 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
BIIB' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.05  Med: 1 Max: 5.31
Current: 0.83
0.05
5.31
Price-to-Peter-Lynch-Fair-Value 0.88
BIIB's Price-to-Peter-Lynch-Fair-Value is ranked higher than
78% of the 63 Companies
in the Global Biotechnology industry.

( Industry Median: 1.49 vs. BIIB: 0.88 )
Ranked among companies with meaningful Price-to-Peter-Lynch-Fair-Value only.
BIIB' s Price-to-Peter-Lynch-Fair-Value Range Over the Past 10 Years
Min: 0.59  Med: 1.43 Max: 18.88
Current: 0.88
0.59
18.88
Price-to-Graham-Number 3.64
BIIB's Price-to-Graham-Number is ranked lower than
68% of the 194 Companies
in the Global Biotechnology industry.

( Industry Median: 2.76 vs. BIIB: 3.64 )
Ranked among companies with meaningful Price-to-Graham-Number only.
BIIB' s Price-to-Graham-Number Range Over the Past 10 Years
Min: 0.25  Med: 2.88 Max: 18.53
Current: 3.64
0.25
18.53
Earnings Yield (Greenblatt) % 9.29
BIIB's Earnings Yield (Greenblatt) % is ranked higher than
94% of the 1060 Companies
in the Global Biotechnology industry.

( Industry Median: -6.86 vs. BIIB: 9.29 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
BIIB' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: 3.1  Med: 7.1 Max: 13.4
Current: 9.29
3.1
13.4
Forward Rate of Return (Yacktman) % 23.74
BIIB's Forward Rate of Return (Yacktman) % is ranked higher than
91% of the 135 Companies
in the Global Biotechnology industry.

( Industry Median: 12.87 vs. BIIB: 23.74 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) % only.
BIIB' s Forward Rate of Return (Yacktman) % Range Over the Past 10 Years
Min: 9.6  Med: 22.9 Max: 26.9
Current: 23.74
9.6
26.9

More Statistics

Revenue (TTM) (Mil) $12,273.90
EPS (TTM) $ 11.94
Beta1.07
Volatility27.80%
52-Week Range $244.28 - 370.57
Shares Outstanding (Mil)211.56

Analyst Estimate

Dec18 Dec19 Dec20
Revenue (Mil $) 12,892 13,130 13,475
EBIT (Mil $) 6,749 7,272 7,232
EBITDA (Mil $) 7,382 7,765 8,262
EPS ($) 24.48 25.72 27.22
EPS without NRI ($) 24.48 25.72 27.22
EPS Growth Rate
(Future 3Y To 5Y Estimate)
8.52%
Dividends per Share ($)

Piotroski F-Score Details

Piotroski F-Score: 55
Positive ROAY
Positive CFROAY
Higher ROA yoyN
CFROA > ROAY
Lower Leverage yoyY
Higher Current Ratio yoyN
Less Shares Outstanding yoyY
Higher Gross Margin yoyN
Higher Asset Turnover yoyN

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}